Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Special-Appointment Assistant Professor
Position
Special-Appointment Assistant Professor
External link
AKEHI Masaru
Degree
-
修士（工学） ( 2011.3 倉敷芸術科学大学 )
Papers
-
Investigating the fate of Zirconium-89 labelled antibody in cynomolgus macaques. International journal
Takanori Sasaki, Sadaaki Kimura, Akihiro Noda, Yoshihiro Murakami, Sosuke Miyoshi, Masaru Akehi, Kazuhiko Ochiai, Masami Watanabe, Takahiro Higuchi, Eiji Matsuura
Nuclear medicine and biology 144-145 109001 - 109001 2025
-
Novel Self-Forming Nanosized DDS Particles for BNCT: Utilizing A Hydrophobic Boron Cluster and Its Molecular Glue Effect Reviewed International journal
Abdul Basith Fithroni, Kazuko Kobayashi, Hirotaka Uji, Manabu Ishimoto, Masaru Akehi, Takashi Ohtsuki, Eiji Matsuura
Cells 11 ( 20 ) 3307 - 3307 2022.10
-
Teratogenicity and Fetal-Transfer Assessment of the Retinoid X Receptor Agonist Bexarotene. International journal
Yuta Takamura, Izumi Kato, Manami Fujita-Takahashi, Midori Azuma-Nishii, Masaki Watanabe, Rui Nozaki, Masaru Akehi, Takanori Sasaki, Hiroyuki Hirano, Hiroki Kakuta
ACS pharmacology & translational science 5 ( 9 ) 811 - 818 2022.9
-
A Novel Zr-89-labeled DDS Device Utilizing Human IgG Variant (scFv): "Lactosome" Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy
Melissa Siaw Han Lim, Takashi Ohtsuki, Fumiaki Takenaka, Kazuko Kobayashi, Masaru Akehi, Hirotaka Uji, Hirotsugu Kobuchi, Takanori Sasaki, Eiichi Ozeki, Eiji Matsuura
LIFE-BASEL 11 ( 2 ) 2021.2
-
Novel single-chain variant of antibody against mesothelin established by phage library
Hiromasa Yakushiji, Kazuko Kobayashi, Fumiaki Takenaka, Yoshiro Kishi, Midori Shinohara, Masaru Akehi, Takanori Sasaki, Eiji Ohno, Eiji Matsuura
CANCER SCIENCE 110 ( 9 ) 2722 - 2733 2019.9
-
F-containing retinoid X receptor (RXR) partial agonist F-CBt-PMN whose tissue transferability is affected by coadministration of another RXR ligand
Yuta Takamura, Osamu Shibahara, Masaki Watanabe, Michiko Fujihara, Masaru Akehi, Takanori Sasaki, Hiroki Kakuta
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 258 2019.8
-
Fluorine-18 (F-18)-labeled retinoid x receptor (RXR) partial agonist whose tissue transferability is affected by other RXR ligands
Yuta Takamura, Osamu Shibahara, Masaki Watanabe, Michiko Fujihara, Shoya Yamada, Masaru Akehi, Takanori Sasaki, Hiroyuki Hirano, Hiroki Kakuta
BIOORGANIC & MEDICINAL CHEMISTRY 27 ( 14 ) 3128 - 3134 2019.7
-
Synthesis of C-11-Labeled RXR Partial Agonist 1-[(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino]benzotriazole-5-carboxylic Acid (CBt-PMN) by Direct [C-11]Carbon Dioxide Fixation via Organolithiation of Trialkyltin Precursor and PET Imaging Thereof (vol 60, pg 7139 , 2017)
Osamu Shibahara, Masaki Watanabe, Yuta Takamura, Shoya Yamada, Masaru Akehi, Takanori Sasaki, Akiya Akahoshi, Takahisa Hanada, Hiroyuki Hirano, Shunsuke Nakatani, Hiromi Nishioka, Yasuo Takeuchi, Hiroki Kakuta
JOURNAL OF MEDICINAL CHEMISTRY 62 ( 9 ) 4780 - 4781 2019.5
-
Novel human anti-mesothelin scFv for cancer targeted therapy
Hiromasa Yakushiji, Kazuko Kobayashi, Fumiaki Takenaka, Masaru Akehi, Eiji Ohno, Eiji Matsuura
CANCER SCIENCE 109 549 - 549 2018.12
-
Anti-high Mobility Group Box 1 Antibody Ameliorates Albuminuria in MRL/lpr Lupus-Prone Mice
Haruki Watanabe, Katsue S. Watanabe, Keyue Liu, Sumie Hiramatsu, Sonia Zeggar, Eri Katsuyama, Noriko Tatebe, Akiya Akahoshi, Fumiaki Takenaka, Takahisa Hanada, Masaru Akehi, Takanori Sasaki, Ken-ei Sada, Eiji Matsuura, Masahiro Nishibori, Jun Wada
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT 6 31 - 39 2017.9
-
Synthesis of C-11-Labeled RXR Partial Agonist 14(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)aminoThenzotriazole-5-carboxylic Acid (CBt-PMN) by Direct [C-11]Carbon Dioxide Fixation via Organolithiation of Trialkyltin Precursor and PET Imaging Thereof
Osamu Shibahara, Masaki Watanabe, Shoya Yamada, Masaru Akehi, Takanori Sasaki, Akiya Akahoshi, Takahisa Hanada, Hiroyuki Hirano, Shunsuke Nakatani, Hiromi Nishioka, Yasuo Takeuchi, Hiroki Kakuta
JOURNAL OF MEDICINAL CHEMISTRY 60 ( 16 ) 7139 - 7145 2017.8
-
Synthesis of 11C labeled RXR partial agonist CBt-PMN by [11C] carbon dioxide fixation via organolithiation of trialkyltin precursor and PET imaging thereof
Osamu Shibahara, Masaki Watanabe, Masaru Akehi, Takanori Sasaki, Takahisa Hanada, Akiya Akahoshi, Hiroyuki Hirano, Hiroki Kakuta
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 254 2017.8
-
Evaluation of brain migration and therapeutic effects of novel RXR partial agonist CBt-PMN on cognitive impairment in mice
Toshiki Kobayashi, Osamu Shibahara, Masaki Watanabe, Shoya Yamada, Masaru Akehi, Takanori Sasaki, Takahisa Hanada, Akiya Akahoshi, Hiroyuki Hirano, Hiroki Kakuta
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 252 2016.8
-
The Function of beta 2-glycoprotein I in Angiogenesis and Its in Vivo Distribution in Tumor Xenografts
Arum Tri Wahyuningsih, Lianhua Shen, Kazuko Kobayashi, Takanori Sasaki, Fumiaki Takenaka, Takahisa Hanada, Masaru Akehi, Akiya Akahoshi, Eiichi Ozeki, Eiji Ando, Eiji Matsuura
ACTA MEDICA OKAYAMA 70 ( 1 ) 13 - 24 2016.2
-
Chiral 1-(1,3-dithian-2-yl) prop-2-en-1-ols: new scaffolds for enantiopure alpha-hydroxyaldehydes
Masaru Akehi, Mariko Kawamoto, Tadakatsu Mandai
TETRAHEDRON 71 ( 37 ) 6488 - 6498 2015.9
-
Positron Emission Tomography to Elucidate Pharmacokinetic Differences of Regioisomeric Retinoid X Receptor Agonists
Toshiki Kobayashi, Yuki Furusawa, Shoya Yamada, Masaru Akehi, Fumiaki Takenaka, Takanori Sasaki, Akiya Akahoshi, Takahisa Hanada, Eiji Matsuura, Hiroyuki Hirano, Akihiro Tai, Hiroki Kakuta
ACS MEDICINAL CHEMISTRY LETTERS 6 ( 3 ) 334 - 338 2015.3
-
Elucidation of the pharmacokinetic difference of regioisomeric retinoid X receptor agonists having an alkoxy group by PET imaging
Toshiki Kobayashi, Kohei Kawata, Mariko Nakayama, Yuki Furusawa, Shoya Yamada, Hiroyuki Hirano, Fumiaki Takenaka, Masaru Akehi, Takanori Sasaki, Eiji Matsuura, Akihiro Tai, Hiroki Kakuta
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 248 2014.8
-
PETイメージングを用いたアルコキシ基を有するレチノイドX受容体アゴニストの体内動態解析
加来田 博貴, 小林 俊貴, 古沢 優貴, 山田 翔也, 竹中 文章, 明日 卓, 佐々木 崇了, 松浦 栄次, 田井 章博
ビタミン 88 ( 4 ) 213 - 213 2014.4
-
アルコキシ基を有するレチノイドX受容体アゴニストの位置異性体間における体内動態差の解明とその応用
小林 俊貴, 古沢 優貴, 山田 翔也, 平野 裕之, 竹中 文章, 明日 卓, 佐々木 崇了, 松浦 栄次, 田井 章博, 加来田 博貴
日本薬学会年会要旨集 134年会 ( 4 ) 81 - 81 2014.3
-
KINETIC RESOLUTION OF SECONDARY ALCOHOLS BY CHIRAL DMAP DERIVATIVES PREPARED BY THE UGI MULTICOMPONENT REACTION
Hiroki Mandai, Shunsuke Irie, Masaru Akehi, Kazunobu Yuri, Masaaki Yoden, Koichi Mitsudo, Seiji Suga
HETEROCYCLES 87 ( 2 ) 329 - 340 2013.2
MISC
-
PETイメージングを用いたRXRパーシャルアゴニストCBt-PMNの脳移行性の評価
芝原 理, 小林 俊貴, 渡邊 将貴, 西井 緑, 明日 卓, 佐々木 崇了, 赤星 彰也, 花田 貴寿, 平野 裕之, 加来田 博貴
日本薬学会年会要旨集 137年会 ( 2 ) 118 - 118 2017.3
Research Projects
-
Zr-89標識イメージング技術に基づく次世代抗体医薬の創生プラットフォームの形成
Grant number：19KK0215 2019.10 - 2023.03
日本学術振興会 科学研究費助成事業 国際共同研究加速基金(国際共同研究強化(B))
佐々木 崇了, 樋口 隆弘, 渡部 昌実, 明日 卓
Grant amount：\18070000 （ Direct expense: \13900000 、 Indirect expense：\4170000 ）
研究はドイツーヴュルツブルグ大学におけるニ重特異性を有する次世代の人工抗体作成技術を導入し、本国研究組織におけるイメージング技術と融合することで、がん特異性を飛躍的に向上させたイメージング基盤技術の創出を目的とする。複数のがん抗原を同時に標的とした放射標識低分子抗体プローブを作成し、2種のがん抗原の重複を可視化することで、特異性と感度を向上させた診断薬を開発する。
2021年度はモデルとなる低分子抗体にキレーター修飾および放射標識を施し、抗体の特異性および安定性を評価した。また新規の腫瘍モデルの検討としてヨウ素のトランスポーターの発現をもちいたモデルの検討を行い、このモデルにおけるプローブとして、I-123（1種）、F-18（2種）、Tc-99m（1種） のプローブをもちいた予備検討を行った。これらのプローブはいずれもヨウ素トランスポーターにより細胞内に取り込まれることを確認し、かつ正常マウスにおける生体分布をPETおよびSPECTにて評価した。 -
Development of a novel radiological-photo-therapy essential for Theranostics targeting deep lesions
Grant number：16K15582 2016.04 - 2018.03
Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research
MATSUURA Eiji, KOBUCHI Hirotsugu, TAKENAKA Fumiaki, AKEHI Masaru
Grant amount：\3510000 （ Direct expense: \2700000 、 Indirect expense：\810000 ）
Photodynamic therapy (PDT) using a photosensitizer capable of inducing cytotoxicity by light irradiation is effective only for the lesion closed to the body surface, due to low permeability of the near infrared light, and is ineffective for therapy targeting the deep tissues. To solve the problem, we studied using Cherenkov light generated by β+-ray emission of a PET nuclide as a internal light source. We have given the PDT effect by Cherenkov light to the innovative "Theranostics (a treatment and diagnostic enforcement) technology" consisting of the specific antibody/Zr-89 labeled-drug delivery system (DDS) that we have ever established. We were newly able to verify some of the new basic technologies to overcome the problem (limit) of the PDT effect.